Intravitreal dexamethasone implant therapy for the treatment of cystoid macular Oedema due to hydroxychloroquine retinopathy: a case report and literature review
- 295 Downloads
Cystoid macular oedema (CMO) is an uncommon complication associated with hydroxychloroquine (HCQ) retinopathy threatening central vision. We report a patient with HCQ retinopathy and CMO, for which an intravitreal dexamethasone implant was used, which led to complete resolution of oedema.
A 57-year-old woman with systemic lupus erythematosus (SLE) complaining of blurred vision in both eyes was diagnosed with bilateral HCQ retinopathy and CMO based on characteristic photoreceptor defects and cystoid spaces on optical coherence tomography, hypo-autofluorescence on fundus autofluorescence, and corresponding visual field defects. After treatment with systemic acetazolamide and topical dorzolamide, CMO showed partial resolution in the right eye. Owing to worsening renal function, an intravitreal dexamethasone implant was placed in the right eye, which resulted in resolution of CMO and visual improvement from 20/50 to 20/30.
Intravitreal dexamethasone implant may be effective for the treatment of CMO in HCQ retinopathy, particularly for the cases refractory to systemic or topical carbonic anhydrase inhibitors.
KeywordsCystoid macular oedema Dexamethasone implant Hydroxychloroquine retinopathy
Best corrected visual acuity
Central foveal thickness
Cystoid macular oedema
Optical coherence tomography
Systemic lupus erythematosus
Hydroxychloroquine (HCQ) is widely used for the treatment of several rheumatologic and dermatologic diseases such as rheumatoid arthritis and systemic lupus erythematosus (SLE).  Retinal toxicity caused by the drug, called HCQ retinopathy, is a well-known condition, characterized by photoreceptor and/or retinal pigment epithelium defects. This is irreversible and progressive in nature, and requires careful and regular screening for early detection. 
Cystoid macular oedema (CMO) in eyes with HCQ retinopathy has been documented in several reports. [2, 3, 4, 5, 6, 7] Kellner et al. reported cases with CMO secondary to HCQ retinopathy,  and the beneficial effect of systemic acetazolamide and topical dorzolamide in one of three patients. However, successful results with systemic or topical carbonic anhydrase inhibitor therapy for CMO associated with HCQ retinopathy have been documented in other, recent reports. [3, 4]
A biodegradable intravitreal dexamethasone implant (Ozurdex; Allergan Inc., Irvine, CA) has shown effectiveness for resolution of macular oedema, including cystoid macular oedema, associated with other aetiologies.  Herein, we report a case of SLE complicated with CMO, for which intravitreal dexamethasone therapy was performed and resulted in complete resolution of CMO without any significant ocular complication. We also summarize the previous reports on the treatment of CMO in eyes with HCQ retinopathy, to highlight the therapeutic efficacy of intravitreal dexamethasone implant for this condition.
Oral acetazolamide (250 mg once a day) therapy was started. One month later, OCT revealed partial resolution of CMO in the right eye, as demonstrated by decrease in the size of cystoid spaces (Fig. 2) and in central foveal thickness (CFT) from 418 to 335 μm, and complete resolution of CMO in the left eye (CFT decreased from 338 to 255 μm). Her BCVA was 20/50 in the right eye and 20/30 in the left. However, her rheumatologist recommended discontinuation of oral acetazolamide due to the risk of aggravation of the patient’s underlying renal issue, lupus nephritis, as her renal function, as measured by glomerular filtration rate, had decreased from 70 to 56 mL/min/1.73 m2 during the one-month period. We discontinued systemic acetazolamide accordingly; topical dorzolamide 2%/timolol maleate 0.5% fixed combination (Cosopt; MSD Korea) twice daily was started in its stead.
Three months later, she complained of worsening of blurred vision. Her BCVA was 20/50 in both eyes, and OCT revealed aggravated CMO, as demonstrated by an increase in CFT, to 427 and 348 μm in the right and left eyes, respectively (Fig. 2). After explaining to her the possible therapeutic options, we treated her with intravitreal injection of 0.7 mg dexamethasone implant (Ozurdex) and discontinued topical dorzolamide in the right eye.
One month after the therapy, the patient reported that her blurred vision had improved; her BCVA was 20/30 in the right eye and 20/40 in the left. Fluorescein angiography (FA) showed decreased leakage in the right eye in the late phase compared to the untreated, fellow eye (Fig. 2). The OCT also revealed regression of CMO in the right eye. CFT in the right eye was decreased to 284 μm, whereas that in the left showed no remarkable change (from 348 to 347 μm). The resolution of CMO persisted up to the last visit, 2 months after the dexamethasone implant was placed. Her intraocular pressure was 15 and 11 mmHg in the right and left eye, respectively, and no other ocular complication was noted at the last visit.
CMO is an uncommon complication of HCQ retinopathy. As patients with HCQ retinopathy usually show parafoveal or pericentral pattern of outer retinal damage, central vision is generally preserved until the condition has progressed to an advanced stage. However, CMO can be a significant threat to vision in this patient group as it involves the central macula. However, whereas HCQ retinopathy is irreversible, appropriate treatment for CMO is possible and imperative to preserve visual function.
Clinical efficacies of various treatment modalities for cystoid macular oedema associated with hydroxychloroquine retinopathy reported in the literature
No. of cases
Kellner et al. (2014)
Topical dorzolamide or systemic acetazolamide (250 mg/day)
- No benefit in 2 of 3
- Of limited structural and functional benefit in 1 of 3
Bhavsar et al. (2015)
Central foveal thickness decreased from 289 to 258 μm (complete resolution) in one eye and from 456 to 325 in the other (partial resolution)
Hong et al. (2016)
Complete resolution of CMO
20/50 to 20/25
Parikh et al. (2016)
- Cessation of HCQ in 1
- Systemic immunosuppression (e.g., steroids, mycophenolate mofetil) and intravitreal triamcinolone in 1
- Resolved after drug cessation
- No response
- Not reported
- 20/30 in the right eye and 20/25 in the left eye
Kim et al. (2018)
Complete resolution of CMO
20/50 OD and 20/40 OS to 20/25 OU in one case,
20/30 OU to 20/25 OD and 20/20 OS in the other
Dexamethasone implants have shown promising results for the treatment of CMO in other retinal degenerative diseases such as retinitis pigmentosa.  In CMO combined with RP, the therapy resulted in complete resolution of CMO, whereas other treatments such as anti-vascular endothelial growth factor therapy resulted in only partial resolution of macular oedema.  Our results, together with those in the literature, suggest that dexamethasone implant therapy is very effective for resolution of macular oedema in eyes with HCQ retinopathy. Although the mechanism of CMO in HCQ retinopathy is unclear, impairment of the blood-retinal barrier (BRB) might be a potential pathogenic mechanism, and the stabilization of the BRB mediated by steroids may have led to resolution of CMO in our case. However, absence of baseline FFA and thus no evidence of fluorescein leakage at baseline in our case makes it impossible to draw a conclusion that the CMO was associated with disruption of the BRB. Further studies should be performed to elucidate the pathogenic mechanism of CMO and the effect of steroid therapy on CMO in HCQ retinopathy. Although our case strongly suggests the CMO-resolving effect of dexamethasone implant, spontaneous resorption of CMO, which can be asymmetric between the treated and untreated eyes, is also possible.
In conclusion, our case suggests that an intravitreal dexamethasone implant can be an effective therapeutic alternative for CMO associated with HCQ retinopathy. Future studies with a larger number of patients and longer follow-up periods are required to assess the efficacy and safety of the treatment.
This study received no specific grant from any funding agency.
No funding was obtained for this study.
Availability of data and materials
All data supporting our findings are provided in the manuscript.
SJA, JJ, SHL, and BRL contributed to conception and design, data acquisition and interpretation of data, SJA and JJ drafted the article, and all authors approved the final version.
Ethics approval and consent to participate
The local ethics committee ruled that no formal ethics approval was required in this case report.
The authors declare that they adhered to the CARE guidelines/methodology.
Consent for publication
Written informed consent for publication of potentially identifying information and clinical images was obtained from the patient.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 1.Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF, American Academy of O. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 2016;123:1386–1394.Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.